Assessing the real-world safety of docetaxel for non-small cell lung cancer: Insights from a comprehensive analysis of FAERS data
PLOS One · 2025
DOI: 10.1371/journal.pone.0331979 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Lei Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jilin Cancer Hospital, Changchun, China. Hauptthemen laut MEDLINE: Docetaxel, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jilin Provincial Scientific and Technological Development Program.
Abstract (Originalsprache)
Background
Docetaxel is a key therapeutic agent in the treatment of non-small cell lung cancer (NSCLC), but comprehensive real-world data on its adverse effects remain scarce. This study aims to evaluate docetaxel-related adverse drug events by analyzing the Adverse Event Reporting System (FAERS) database of the U.S. Food and Drug Administration (FDA) from 2004 to 2024.
Methods
This study utilized descriptive analysis along with four heterogeneity analysis methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Multivariate Gamma-Poisson Shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN), to systematically analyze 1,535 adverse event reports.
Results
The results identified potential adverse reactions associated with docetaxel that were not included in the drug label, such as dehydration, leukopenia, acute kidney injury, and hemoptysis, in addition to well-established adverse effects. Subgroup analysis revealed that male patients were more likely to experience respiratory-related adverse events, while female patients had a higher incidence of endocrine, metabolic, and skin-related adverse events. Patients aged over 65 years exhibited an elevated risk of cardiovascular and respiratory complications.
Conclusion
These findings offer critical evidence for the individualized monitoring and risk management of docetaxel in clinical practice, providing healthcare professionals with the necessary information to optimize treatment regimens and ensure the safe use of docetaxel.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jilin Cancer Hospital, Changchun, China.
- Changchun University of Chinese Medicine, Changchun, China.
- Tianjin Medical University, Tianjin, China.
ORCID-Profile: Bao Wang
Förderung
- Jilin Provincial Scientific and Technological Development Program
Zitieren
APA
Wang, L., Zhao, H., Yang, K., Wang, Z., Cai, C., Lv, P., & Wang, B. (2025). Assessing the real-world safety of docetaxel for non-small cell lung cancer: Insights from a comprehensive analysis of FAERS data. PLOS One. https://doi.org/10.1371/journal.pone.0331979
Vancouver
Wang L, Zhao H, Yang K, Wang Z, Cai C, Lv P, et al. Assessing the real-world safety of docetaxel for non-small cell lung cancer: Insights from a comprehensive analysis of FAERS data. PLOS One. 2025. doi:10.1371/journal.pone.0331979
BibTeX
@article{Wang2025,
author = {Wang, Lei and Zhao, Hui and Yang, Kunpeng and Wang, Zhe and Cai, Chenglun and Lv, Peiyun and Wang, Bao},
title = {Assessing the real-world safety of docetaxel for non-small cell lung cancer: Insights from a comprehensive analysis of FAERS data},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0331979}
}
EUVIMED